EGFR and non-small cell lung carcinoma: However, the current evaluation methods and periods of EGFR mutation and/or ALK rearrangement, as well as the first‐line targeted therapy rate in patients with NSCLC harboring EGFR mutations or ALK rearrangement in China remain unclear.